Introduction
Stolte's seminal study, published in 1944, of 1832 patients seen since 1976, with three pre-defined peptic ulcer patients seen between 1899 and 1939, aims. First, to determine the incidence of bleeding. showed bleeding was a common event at some stage Second, to study the risk of bleeding for the first in the illness, the incidence rising with time to a time in patients who had presented with pain, peak of 86% in those followed for up to 30 years. 1 compared with the risk of rebleeding in patients who Moore (1950) confirmed these findings, and further had presented with haemorrhage. Third, to investiobserved that patients who bled were at much greater gate the influence of H2RA maintenance treatment risk of doing so again, compared with those preon these risks. senting with pain (13% vs. 2.1%).2 It is widely believed that the natural history of duodenal ulcer has changed over the years, and the introduction of Methods H2RA in late 1976 dramatically increased our ability to control the disease. There is little information,
Survey period
however, as to whether the risk of rebleeding has
We surveyed patients with duodenal ulcer, endoreally changed.
We prospectively followed all our duodenal ulcer scopically or surgically proven, seen between 1976 and 1993. Almost all patients with peptic ulcer regularly they were contacted for telephone interview or by postal questionnaire, and seen again if they disease seen in this hospital have been prospectively followed-up in our unit. Those originally referred to became symptomatic. Where necessary, for clarification, treatment details were obtained from their other consultants were transferred to our care; therefore, management and data collection were uniform. general practitioners. Approximately 15% of all patients were followed-up in this manner. A few patients who had left the Rotherham area were also
Inclusion and exclusion criteria contacted by postal questionnaire. Only patients in whom duodenal ulcer was the sole lesion both at presentation and in the event of
Data presentation
recurrence were included in this study. Those with associated gastric ulcer and/or gastroesophageal To make our results comparable with other studies, reflux disease were excluded, to avoid confounding we have presented the incidence of bleeding/rebleedvariables.
ing on follow-up as a proportion of the particular patient group as a whole, as well as in the subset Management with ulcer relapse.
Initial treatment

Terminology
Haemorrhage was treated on standard lines. All patients (other than those operated upon) were For convenience of describing long-term outcome, treated with H2 receptor antagonists (H2RA), mainly patients who presented with haemorrhage are cimetidine 1 g daily (and in a few, ranitidine referred to as group I, and the others as group II. 300 mg), for ulcer healing. More recently, the protonpump inhibitor (PPI) omeprazole (20 mg daily) has been the drug of choice. Most patients were
Results
re-endoscoped 1-3 months later, and if the ulcer was still active, treatment was extended for approxi-
Patients analysed mately a further 3 months at the same or higher
This survey is based exclusively on the 2119 patients dose (cimetidine 2 g, 3.2 g; ranitidine 600 mg, with duodenal ulcer (DU) alone. The 1638 patients 900 mg; omeprazole 40 mg) and the cycle was with DU and other lesions (e.g. gastric ulcer and/or repeated where necessary.
gastroesophageal reflux disease) were excluded from detailed analysis, although some of their data are
Long-term therapy
shown for comparison. None of the 2119 patients After healing was confirmed, patients had either with DU alone had Zollinger Ellison Syndrome or intermittent or maintenance treatment. In earlier post-bulbar ulcer. years, the safety of long-term H2RA therapy was unknown; therefore, intermittent treatment was used more often. With time, maintenance treatment with Presentation and demography cimetidine was used increasingly (400 mg nightly, Of the 2119 patients with DU alone, 286 (13.5%) the standard low dose, or, in a subset, full dose of presented with haemorrhage as the first manifestation 1 g daily), particularly in the elderly, in patients who of ulcer disease (group I). This compared with had bled and those who had relapsed at the lower 185/1638 (11%) of patients with DU plus other dose or had proven refractory disease (i.e. failure to lesions. Group I patients were older (age Á65: 40% heal within 3 months). The alternative, in fewer vs. 17%), more were men (351 vs. 1.951), and more patients, was ranitidine 150 mg nightly (low dose) used non-steroidal anti-inflammatory drugs (NSAID) or 300 mg per day (full dose). Some had maintenance (32% vs. 4%); but there were fewer smokers (49% omeprazole 20 mg daily. A few patients who had vs. 71%) and fewer with a family history of ulcer presented with pain participated in clinical trials of disease (22% vs. 46%) ( Table 1 ). maintenance treatment with colloidal bismuth or misoprostol.
Early outcome in group I (Figure 1)
Surveillance and further treatment Early mortality
Patients had periodic check endoscopy approximately yearly, if asymptomatic, or whenever sympSeven patients (2.4%) died shortly after being brought to hospital and a further six post-operatively, from toms arose. The treatment cycle was repeated upon ulcer recurrence.
their associated severe illnesses. Thus, the early mortality was 4.5% (13/286). When patients became too old or infirm to attend On maintenance treatment Table 2 pools the outcome of all 926 group II patients on maintenance therapy, regardless of drugs used; Table 3 shows the results of maintenance treatment with H2RA (and at different doses) and omeprazole (and excludes 44 patients treated with other drugs). DU relapse rates were lower on maintenance treatment, compared with patients off therapy. The reduction was greater on full-dose than on low-dose H2RA, and greatest in patients on omeprazole. DU recurrence more rebled on ulcer relapse compared with group II, as follows: 4% vs. 0.7% on low-dose H2RA and 4%
Early surgery
vs. 0.4% on full-dose H2RA. None bled on maintenance treatment with omeprazole. Thirty-eight patients were operated upon: 33 had Pooling the data from all patients on maintenance definitive surgery; five had under-running of vessels treatment, irrespective of drug and dose used, 5/48 (including two in whom an associated perforation (10%) of group I re-bled on relapse, compared with was repaired).
only 5/488 (1%) of group II. Life-table analysis ( Figure 2 ) confirms that fewer
Medical treatment
group I patients relapsed compared with group II Two hundred and forty-six patients were treated patients ( p<0.01), yet proportionately more re-bled medically, mainly with H2RA (including the five ( p<0.01). This increased risk of rebleeding persisted patients who had had vessels under-run).
during follow-up.
Healing on medical treatment
Rebleeding: a different perspective (Table 4) The DU healed in 227/246 (92%), most within 3 months; 17 were refractory. Healing could not be The increased risk of rebleeding in group I patients has been calculated in different ways. It ranged from assessed in 19 patients: eight died, five defaulted, one stopped treatment for side-effects of drug 3.9-fold greater in the entire patient group, to 6.8-fold greater when viewed as risk of bleeding per ulcer therapy, one bled (see below) and four were still on healing therapy at the time the survey closed. This relapse. Figure 2 . The probability of ulcer relapse and the risk of (re)bleed, calculated by life-table analysis. The patients were followed up to their first relapse or until the end of the survey. The percentage figure in the rectangles is the cumulative probability of relapse at 10 years. Ex-bleed=group I; ex-pain=group II.
rebleeds occurred at the first ulcer relapse, and the
The changing risk of bleeding over time remaining one-third over the next 112 ulcer recurNinety-eight group I patients had 210 ulcer relapses;
rences. The risk of rebleeding, therefore, was 15.3% 21 of these 98 patients rebled, two patients twice, (15/98) at the first ulcer relapse, decreasing to only 7.1% (8/112) subsequently. i.e. a total of 23 rebleeds. Two-thirds (n=15) of the 
Mortality Incidence of bleeding at presentation
Mortality in group I patients was higher than in group II patients, both early on and during followOur observed incidence of 13.5% falls in the range up; early mortality was ulcer-related, whereas subof 3.5-34% reported in earlier series, and is similar sequent deaths were from other causes.
to the 15% noted in a recent large study.5
Early mortality
Cumulative incidence of bleeding on
In group I, 4.5% of patients (13/286) died, compared follow-up with 1% (19/1833) in group II. Most of the deaths in the former were related to bleeding and The historical evidence is that the incidence rises co-morbidity. In contrast, 17/19 deaths in group II with the length of follow-up. Based on patients seen patients followed ulcer perforation (and two were 40-50 years ago, the incidence calculated was for unconnected reasons).
approximately 15% in the first 10 years, rising to 25->40% after 20 years or longer1,6-10 (see review5).
Mortality on follow-up
Three more recent studies show a broadly similar pattern: Elashoff (1983), 27% after a six-year followTwenty-two per cent (61/273) of the group I patients died, compared with 15% (272/1814) group II up (the figure including hospitalization, perforation and bleed);11 Penston & Wormsley (1992) , 13% patients. None of group I died from rebleeding or ulcer-related problems. In contrast, four deaths in (patients not on maintenance treatment);5 and Peterson et al. (1995) 10%;12 the latter two studies group II were ulcer-related (three with perforation and one with bleeding). Deaths from other causes had a seven-year follow-up. Our experience, however, is somewhat different. were similar in both groups.
Only 3.3% of our patients bled during a follow-up patients with both DU and reflux, the higher-dose therapy may mask the natural history of the ulcer extending in some cases for up to 18 years, and mainly in patients who had originally presented with disease. haemorrhage. Presumably maintenance treatment with H2RA made a difference, but a change in Bleeding duodenal ulcer: a special natural history cannot be excluded.
subgroup?
A common perception is that haemorrhage occurs Effect of maintenance treatment on risk of when duodenal ulcer becomes chronic, repeated rebleeding episodes of ulceration going progressively deeper into the tissues and eroding into vessels, i.e. a timeMaintenance treatment markedly reduced the inciddependent mechanical process. This view is supence of bleeding on follow-up: 3.3% on treatment ported by the rising cumulative incidence of bleeding vs. 12.8% off therapy. The protection against haemorwith prolonged follow-up (see earlier section). Our rhage is presumably due to reduction in ulcer relapse findings and those of others5,12 suggest in addition, rates, thus decreasing the number of patients at risk.
that such patients have a particular propensity to Our results are similar to those of Penston & bleed independent of chronicity. The reasons are, Wormsley5 and Jensen et al. 13 Both observed that first, bleeding may be the initial ulcer manifestation; interruption of maintenance treatment was followed second, the risk of rebleeding is greatest at the next by frequent ulcer relapse, often complicated with ulcer relapse; third, such ulcers relapse less often, further bleeding.
yet paradoxically are more likely to bleed. Off therapy, the propensity to ulcer relapse was similar in group II (71%) and in group I (64%)
Practical management
patients. The latter group is commonly perceived as having more aggressive disease, yet maintenance Our data show that DU patients who survive the treatment was more effective in preventing ulcer initial haemorrhage respond well to medical treatrecurrence than it was in patients who presented ment; most ulcers heal swiftly. The spontaneous with pain, and the effect was dose-related.
relapse rate is high, but maintenance treatment, particularly at full-dose H2RA (and even more so
Increased risk of rebleeding in patients
with proton-pump inhibitors), markedly reduces relapse rates and so protects against further haempresenting with haemorrhage orrhage. As mentioned earlier, Moore2 observed a markedly Our study reflects the natural history of DU in the increased risk of bleeding in patients presenting with period of major therapeutic advance with H2RA and haemorrhage as opposed to pain, 13% vs. 2.1%, PPI. Since the completion of our survey, the emphasis relative risk (RR) 6.2. This phenomenon holds true of DU treatment has moved to anti-Helicobacter today. In our series, it was 10.9% vs. 1.6% per ulcer pylori therapy. This organism is almost invariably relapse (RR 6.8). Four other recent studies showed a present in uncomplicated DU. It seems less prevalent, similar increased risk: Elashoff (1983) , 27% vs. 8% however, in patients with haemorrhage, thus redu-(RR 3.4; this series included haemorrhage, perforation cing the scope of disease-curative antibacterial treatand hospitalization);11 Battaglia (1992) 
